Open Access Open Access  Restricted Access Subscription or Fee Access

PARP Inhibitor in treatment of Breast cancer

Nidhi Singh Singh

Abstract


Breast cancer is the most common cancer among women. It accounts for approximately about 14% in all
types of cancer. Poly (ADP-ribose) polymerases (PARP) are enzymes (a nuclear protein) involved in DNA-
damage repair. It is a small-molecule inhibitors which are thought to mediate their antitumor effect as a
catalytic inhibitor that blocks repair of DNA single strand break. Inhibition of PARP for treating breast
cancer is a promising strategy. PARP inhibition is a therapeutic approach to selectively kill a subset of cancer
which has deficiencies in DNA repair pathway including Brca1 and Brca2 mutated breast cancer and ovarian
cancer. Several PARP inhibitors are currently in trial in adjuvant, neoadjuvant and metastatic setting. PARP
inhibitors are first clinically approved drugs designed to exploit synthetic lethality. Wherein the current
understanding of PARP inhibitors is evaluated or discussed, including their effectiveness, side effects, and
safety. antitumor activity as a single agent or in combination and mechanism of acquired resistance to PARP
inhibitors. PARP inhibitor plus chemotherapy and PARP inhibitor plus immunotherapy are novel approaches
which are also under study.


Full Text:

PDF

References


Sulai N.H, Tan A.R, Development of Poly (ADP- Ribose) Polymerase Inhibitors in Treatment

of BRCA-Mutated Breast Cancer. Clinical Advances in Hematology and Oncology 2018;

:491-501.

Rugo HS, Olopade OI, DEMicheleA, et al; I-SPY2 Investigators. Adaptive randomization of

veliparib-carboplatin treatment in breast cancer. New England journal Medicine.2016;

(1):23-34.

Curigilano.G, Goldhirsch.A. The Triple Negative Subtype: New ideas for the Poorest

Prognosis Breast Cancer. J Natl Cancer InstMonugr 2011; 43:108-110.

Lord C.J, Ashworth A, PARP Inhibitors: Synthetic Lethality in the Clinic. Science 2017;

:1152-1158.

Boraei Ahmed T.A, Singh P.K, et al. Discovery of novel functionalized 1, 2, and 4 - triazoles

as PARP-1 Inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.

European journal of Medicinal Chemistry 2019;182:11621

Murai.J, Huang S.N, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

American Associated for Cancer Research 2012; 72:5588-5599.

Livraghi.L, GarberJ.E. PARP Inhibitors in the management of Breast cancer: Current data and

future prospects. BMC Medicine 2015; 13:188.

Kaufman B, Shapir-Frommer R, et al. Olaparib monotherapy in patients with advanced cancer

and a germline BRCA1/2 mutation. JClinoncol 2015; 33:244-50.

DeMichele.A. Current and Emerging role of PARP Inhibitors in Breast Cancer. The American

Journal of Hematology 2017; 13:9.

Robson M, Im S.A., et al. Olaparib for Metastatic Breast cancer in patients with Germline

Mutation. The New England journal of Medicine 2017.

Litton J, Rugo HS, Ettl J et al. EMBRACA. A phase 3 trial comparing Talazoparib, an oral

PARP Inhibitor, to physician's choice pf therapy in patients with advanced breast cancer and a

germline BRCA mutation. Presented at: 40 th Annual San Antonio Breast cancer Symposium;

December 5-9, 2017; San Antonio, TX. Abstract GS6-07.

Turner NC, Telli ML, Rugo HS et al. Final results of a phase 2 study of talazoparib following

platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline

BRCA1/2 mutation. (ABRAZO) [ASCOabstract1007]. J ClinOncol. 2017; 35(15).

BouwmanP, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant

to PARP Inhibitors? Clin cancer Res.2014; 20 (3):540-547.

PatsoriousA, Vicier P, Campion L, et al. An open-label, phase 2 study of rucaparib a PARP

inhibitor, in HER2-Metastatic breast cancer patients with high genomic loss of heterozygosity:

RUBY [ASCO abstract TPS1117]. J ClinOncol. 2017; 35(15).

Kuchenbaecker K.B., Hopper J.L, et al. Risk of Breast, Ovarian, and contra lateral Breast

cancer for BRCA1 and BRCA2 Mutation carriers. JAMA 2017; 317:23.

Johnson N, Li YC et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to

PARP inhibition. Nat Med.2011; 17(7):875-882.

Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-Ribose) Polymerase Inhibitor olaparib in

patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept

trial. Lancet 2010; 376:235-44.

Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade

serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: non-

randomised study. Lancet oncol 2011; 12:852-61.

Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive

recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated

analysis from a randomized, placebo- controlled, double-blind, phase 2 trial. Lancet oncol

; 17: 1579-89.


Refbacks

  • There are currently no refbacks.